Translate Bio Announces Timing of Interim Results from mRNA Therapeutic Clinical Trial in Patients with Cystic Fibrosis; Data Expected in Early Q2 2021

NEXT STORY
Konica Minolta Healthcare and AGIMED to Implement PACS Across 34 Hospitals in Córdoba, Argentina
PREV STORY
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Todos Medical Announces US FDA Emergency Use Authorization Allowed for Gnomegen COVID-19 PCR Test Kits

author_avatar
NASDAQ Market News

Parkinson’s Disease Pathogenesis may have a Bacterial Virus Component According to Research Conducted by Human Microbiology Institute

Full study data published in Scientific ReportsNEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- ...

author_avatar
NASDAQ Market News

AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients

BROOKLYN, N.Y., Nov. 17, 2016 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc. (NASDAQ:AZRX) (“AzurRx” or ...

author_avatar
NASDAQ Market News